ReviewCellular and molecular neurobiology1994
Inhibition of gene expression with ribozymes.
Review in Cellular and molecular neurobiology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 80 citations in OpenAlex.
- Non-invasive single cell aptasensing in live cells and animals.Chemical science · 2024Article
- A modular and extensible RNA-based gene-regulatory platform for engineering cellular function.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis.Journal of clinical immunology · 2002Article
- Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.Gene therapy · 2001Article
- Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.Nucleic acids research · 1997Article
- Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates.Nucleic acids research · 1997Article
- Strategy for designing specific antisense oligonucleotide sequences.Journal of gastroenterology · 1997Review
- Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase.Nucleic acids research · 1996Article
- Specificity of hammerhead ribozyme cleavage.The EMBO journal · 1996Article
- Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes.Nucleic acids research · 1996Article
- Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure.Nucleic acids research · 1996Article
- Ribozyme-mediated RNA degradation in nuclei suspension.Nucleic acids research · 1995Article
- Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes.Nucleic acids research · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Ribozymes can be designed to cleave in trans, i.e. several substrate molecules can be turned over by one molecule of the catalytic RNA. Only small molecular weight ribozymes, or small ribozymes, are discussed in this review with particular emphasis on the hammerhead ribozyme as this has been most widely used for the inhibition of gene expression by cleavage of mRNAs. 2. Cellular delivery of the ribozyme is of crucial importance for the success of inhibition of gene expression by this methodology. Two modes of delivery can be envisaged, endogenous and exogenous delivery. Of the former several variants exist, depending on the vector used. The latter is still in its infancy, even though chemical modification has rendered such ribozymes resistant against degradation by serum nucleases without impairment of catalytic efficiency. 3. Various successful applications of ribozymes for the inhibition of gene expression are discussed, with particular emphasis on HIV1 and cancer targets. These examples demonstrate the promise of this methodology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.